Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study
Treatment in the home and hospice of long-term care facilities, particularly for
non-ambulatory patients, could provide significant advantages for patients and for the
region. The Calgary Health Region has a unique resource in the home parenteral therapy
program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment
for the management of TIH or MBP could be treated in the community (ie at home). However,
the resources required and the costs associated with community-based (homes, hospices,
long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so
as to guide future regional decision making.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
feasibility of treating hypercalcemia in the community
Jose Pereira, MD
Principal Investigator
Alberta Cancerboard
Canada: Health Canada
17280
NCT00126386
January 2004
September 2006
Name | Location |
---|